Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology

Volumn 71, Issue 3, 2014, Pages 484-492

  Krupashankar, D S ^a   Dogra, Sunil ^b   Kura, Mahendra ^c   Saraswat, Abir ^d   Budamakuntla, Leelavathy ^e   Sumathy, T K ^f   Shah, Radha ^g   Gopal, M G ^h   Narayana Rao, T ⁱ   Srinivas, C R ^l   Bhat, Ramesh ^m   Shetty, Narendra ⁿ   Manmohan, G ^o   Sai Krishna, Kotla ^p   Padmaja, Dalavoi ^q   Pratap, Dasiga Venkata Subrahmanya ^r   Garg, Vijay ^s   Gupta, Sandesh ^t   Pandey, Neeraj ^u   Khopkar, Uday ^v   Montero, Enrique ^j,k   Ramakrishnan, M S ^k   Nair, Pradip ^k   Ganapathi, Prasanna C ^k   more..

^a MANIPAL HOSPITAL   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c SIR J J GROUP OF HOSPITALS   (India)

^d Indushree Skin Clinic   (India)

^e Bowring and Lady Curzon Hospitals   (India)

^f Medical College   (India)

^g APOLLO HOSPITAL   (India)

^h KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ King George Hospital   (India)

^j CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^k Molecular Characterization Analytical Group   (India)

^l Department of Fashion Technology   (India)

^m FATHER MULLER MEDICAL COLLEGE   (India)

ⁿ A J INSTITUTE OF MEDICAL SCIENCES   (India)

^o Derma Skin Clinic   (India)

^p Sri Sai Skin Clinic   (India)

^q Sumana Hospital   (India)

^r Department of Cardiology   (India)

^s LOK NAYAK HOSPITAL   (India)

^t Skin Laser Center   (India)

^u Laser and Cosmetic Clinic   (India)

^v KEM HOSPITAL   (India)

more..

Author keywords

anti CD6; autoimmune disease; itolizumab; monoclonal antibody; psoriasis; Psoriasis Area and Severity Index

Indexed keywords

ITOLIZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; CONTROLLED STUDY; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; DIABETES MELLITUS; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHRODERMA; ERYTHRODERMIC PSORIASIS; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SHORT FORM 36; SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AGED; CHRONIC DISEASE; CLINICAL TRIAL; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906313997     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.01.897     Document Type: Article

References (26)

1. M.H. Buch, S.J. Bingham, D. Bryer, and P. Emery Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders Rheumatology (Oxford) 46 2007 1153 1156
2. E. Molloy, S. Ramakrishnan, E. Murphy, and M. Barry Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab Rheumatology (Oxford) 43 2004 522 523
3. E. Montero, R. Melarkode, P. Nair, R. Alonso, A. Anand, and P. Hernandez et al. CD6 targeted immunotherapy controls inflammation in autoimmune diseases J Clin Immunol 31 2011 S16 S17
4. P. Nair, R. Melarkode, D. Rajkumar, and E. Montero CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction Clin Exp Immunol 162 2010 116 130
5. I. Gimferrer, M. Calvo, M. Mittelbrunn, M. Farnós, M.-R. Sarrias, and C. Enrich et al. Relevance of CD6-mediated interactions in T-cell activation and proliferation J Immunol 173 2004 2262 2270
6. I. Gimferrer, A. Ibanez, M. Farnós, M.-R. Sarrias, R. Fenutría, and S. Roselló et al. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains J Immunol 175 2005 1406 1414
7. A. Ibanez, M.-R. Sarrias, M. Farnós, I. Gimferrer, C. Serra-Pagès, and J. Vives et al. Mitogen-Activated protein kinase pathway activation by the CD6 lymphocyte surface receptor J Immunol 177 2006 1152 1159
8. M.A.A. Castro, M.I. Oliveira, and R.J. Nunes Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse J Immunol 178 2007 4351 4361
9. P. Nair, A. Ghorai, L. Adhikary, R. Melarkode, and E. Montero The inhibition of T cell proliferation in a mixed lymphocyte reaction by itolizumab (T1h) is associated with reduction in pro inflammatory cytokines and CD6 internalization J Immunol 186 2011 52.27
10. L.M. Osorio, C.A. Garcia, M. Jondal, and S.C. Chow The anti-CD6 mAb, ior-t1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation Cell Immunol 154 1994 123 133
11. C.A. García, A.M. Barral, and K. Torres El anticuerpo monoclonal ior t1 reconoce un epítope dentro del CD6 antígenos de diferenciación leucocitario humano Biotecnología Aplicada 9 1992 70 77
12. L. Roque-Navarro, C. Mateo, J. Lombardero, G. Mustelier, A. Fernández, and K. Sosa et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method Hybrid Hybridomics 22 2002 245 257
13. R. Alonso, V. Huerta, J. de Leon, P. Piedra, Y. Puchades, and O. Guirola et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody Hybridoma (Larchmt) 27 2008 291 301
14. E. Montero, L. Falcon, Y. Morera, J. Delgado, J.F. Amador, and R. Perez CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease Autoimmunity 29 1999 155 156
15. R. Alonso-Ramirez, S. Loisel, C. Buors, J.O. Pers, E. Montero, and P. Youinou et al. Rationale for targeting CD6 as a treatment for autoimmune diseases Arthritis 2010 2010 130646
16. A. Anand, D. Assudani, P. Nair, S. Krishnamurthy, S. Deodhar, and A. Arumugam et al. Safety, efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis-results from a randomized phase II trial [abstract] J Immunol 184 2010 96.13
17. M.C. Genovese, M. Schiff, M. Luggen, J.-C. Becker, R. Aranda, and J. Teng et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy Ann Rheum Dis 67 2008 547 554
18. Shankar G. Harmonized terminology and reporting of clinical immunogenicity (draft AAPS Therapeutic Protein Immunogenicity Focus Group whitepaper). Paper presented at: Fifth Open Scientific European Immunogenicity Platform Symposium, February 27, 2013. Available at: http://www.e-i-p.eu/wp- content/uploads/2013/02/symposium-2013-Munich-Gopi-Shankar.pdf. Accessed February 10, 2014.
19. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
20. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
21. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, G. Guzzo, and Y. Wang et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
22. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
23. TB India 2012 (annual status report of the revised national TB control program). Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. March 2012. Available from: URL: http://tbcindia.nic.in/pdfs/TB%20India%202012-%20Annual%20Report.pdf. Accessed May 20, 2013.
24. Enbrel [package insert]. Immunex Corp and Wyeth-Ayerst Laboratories Thousand Oaks, CA 2012. Available from: URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/103795s5507lbl.pdf. Accessed May 20, 2013.
25. Goffe B. Etanercept (Enbrel)-An update. Available from: URL: http://www.skintherapyletter.com/2004/9.10/1.html. Accessed May 20, 2013.
26. K. Reich, F.O. Nestle, K. Papp, J.-P. Ortonne, R. Evans, C. Guzzo for the EXPRESS Study Investigators Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial Lancet 366 2005 1367 1374